Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Iron deficiency may impair aerobic performance. This study aimed to determine whether treatment with intravenous iron (ferric carboxymaltose) would improve symptoms in patients who had heart failure, reduced left ventricular ejection fraction, and iron deficiency, either with or without anemia. METHODS: We enrolled 459 patients with chronic heart failure of New York Heart Association (NYHA) functional class II or III, a left ventricular ejection fraction of 40% or less (for patients with NYHA class II) or 45% or less (for NYHA class III), iron deficiency (ferritin level <100 microg per liter or between 100 and 299 microg per liter, if the transferrin saturation was <20%), and a hemoglobin level of 95 to 135 g per liter. Patients were randomly assigned, in a 2:1 ratio, to receive 200 mg of intravenous iron (ferric carboxymaltose) or saline (placebo). The primary end points were the self-reported Patient Global Assessment and NYHA functional class, both at week 24. Secondary end points included the distance walked in 6 minutes and the health-related quality of life. RESULTS: Among the patients receiving ferric carboxymaltose, 50% reported being much or moderately improved, as compared with 28% of patients receiving placebo, according to the Patient Global Assessment (odds ratio for improvement, 2.51; 95% confidence interval [CI], 1.75 to 3.61). Among the patients assigned to ferric carboxymaltose, 47% had an NYHA functional class I or II at week 24, as compared with 30% of patients assigned to placebo (odds ratio for improvement by one class, 2.40; 95% CI, 1.55 to 3.71). Results were similar in patients with anemia and those without anemia. Significant improvements were seen with ferric carboxymaltose in the distance on the 6-minute walk test and quality-of-life assessments. The rates of death, adverse events, and serious adverse events were similar in the two study groups. CONCLUSIONS: Treatment with intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, improves symptoms, functional capacity, and quality of life; the side-effect profile is acceptable. (ClinicalTrials.gov number, NCT00520780).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, parenteral iron substitution has been found to improve the clinical course of CHF in patients with coexisting ID [22–24].”
From Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation (2016) · cites this paper as [24]
In the citing paper
“We are aware that anemia is a complication of iron deficiency, though not the only one, since other tissues/organs may be iron-depleted before anemia develops, as occurs in chronic heart failure.75”
From Iron metabolism and iron disorders revisited in the hepcidin era (2020) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Regression Models for Ordinal Data
McCullagh, P. (1980) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1980.tb01109.x · Cited by 4,453
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
Dickstein, K., Authors/Task Force Members, Cohen-Solal, A., Filippatos, G., McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., Strömberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.08.005 · Cited by 3,512
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Trends in Heart Failure Incidence and Survival in a Community-Based Population
Roger, V. L. (2004) · JAMA · doi:10.1001/jama.292.3.344 · Cited by 1,600
Jessup, M., & Brozena, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021498 · Cited by 1,564
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.013 · Cited by 1,374
Haas, J. D., & Brownlie, T. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.2.676s · Cited by 1,186
Research works printed but not linked: 4
- Fairbanks V, Beutler E. Iron deficiency. In: Beutler E, ed. Williams hematology. 6th ed. New York: McGraw-Hill, 2001:295-304, 447-70.
- Davies KJ, 1982, Am J Physiol, 242, E418
- Usmanov RI, 2008, J Nephrol, 21, 236
- Ganzoni AM, 1970, Schweiz Med Wochenschr, 100, 301
Cited by
Items 601–700 of 1,002
Martens, P. (2022) · Cardiac failure review · doi:10.15420/cfr.2021.26 · Cited by 33
Anaemia in chronic obstructive pulmonary disease: an insight into its prevalence and pathophysiology
Boutou, A., Hopkinson, N. S., & Polkey, M. I. (2014) · Clinical Science · doi:10.1042/cs20140344 · Cited by 34
Anemia in Heart Failure: Association of Hepcidin Levels to Iron Deficiency in Stable Outpatients
Weber, C. S., Neto, L. B. D. S., Goldraich, L. A., Biolo, A., & Clausell, N. (2012) · Acta Haematologica · doi:10.1159/000342110 · Cited by 28
Impact of iron deficiency on long-term clinical outcomes of hospitalized patients with heart failure
Nakano, H., Nagai, T., Sundaram, V., Nakai, M., Nishimura, K., Honda, Y., Honda, S., Iwakami, N., Sugano, Y., Asaumi, Y., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.03.039 · Cited by 28
Koo, H. M., Kim, C. H., Doh, F. M., Lee, M. J., Kim, E. J., Han, J. H., Han, J. S., Oh, H. J., Park, J. T., Han, S. H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087231 · Cited by 31
2009: A Requiem for rHuEPOs—But Should We Nail Down the Coffin in 2010?
Goldsmith, D. J. A. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09131209 · Cited by 27
Heart failure 2016: still more questions than answers
Metra, M., Carubelli, V., Ravera, A., & Coats, A. J. S. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.10.060 · Cited by 32
Dhoot, S., Mittal, S., Singh, S. P., Patel, V., Kasliwal, R. R., & Mehta, V. (2020) · Future Science OA · doi:10.2144/fsoa-2019-0156 · Cited by 27
“In FAIR-HF [7], consistent improvement starting from as early as 4 weeks and persisting at 12 and 24 weeks was seen (all p < 0.”
MethodResultInfluentialAnemia in heart failure: still an unsolved enigma
Sharma, Y. P., Kaur, N., Kasinadhuni, G., Batta, A., Chhabra, P., Verma, S., & Panda, P. K. (2021) · The Egyptian Heart Journal · doi:10.1186/s43044-021-00200-6 · Cited by 30
Lindberg, F., Lund, L. H., Benson, L., Dahlström, U., Karlström, P., Linde, C. M., Rosano, G. M. C., & Savarese, G. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2644 · Cited by 31
Lucas, S. E., & Garg, M. (2023) · Internal Medicine Journal · doi:10.1111/imj.16184 · Cited by 31
“28 Overall, the real-world incidence is likely to be much lower but remains unclear.”
BackgroundMarques, P. S., Matias, P., Packer, M., Vieira, J. T., Vasques‐Nóvoa, F., Sharma, A., Mavrakanas, T. A., Friões, F., & Ferreira, J. P. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2992 · Cited by 27
Pöss, J., Jacobshagen, C., Ukena, C., & Böhm, M. (2010) · Clinical Research in Cardiology · doi:10.1007/s00392-010-0176-0 · Cited by 31
Peck, K. Y., Lim, Y. Z., Hopper, I., & Krum, H. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.02.014 · Cited by 27
Przybyłowski, P., Wasilewski, G., Gołąbek, K., Bachórzewska-Gajewska, H., Dobrzycki, S., Koc‐Żórawska, E., & Małyszko, J. (2016) · Transplantation Proceedings · doi:10.1016/j.transproceed.2015.12.023 · Cited by 30
Walden, R., & Tomlinson, B. (2011) · Oxidative stress and disease · doi:10.1201/b10787-17 · Cited by 31
Elendu, C., Amaechi, D. C., Elendu, T. C., Fiemotonghan, B.-E., Okoye, O. K., Agu-ben, C. M., Onyekweli, S. O., Amapu, D. A., Ikpegbu, R. C., Asekhauno, M. O., et al. (2024) · Medicine · doi:10.1097/md.0000000000036895 · Cited by 34
Shrestha, K., Borowski, A., Troughton, R., Klein, A., & Tang, W. H. W. (2012) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2012.00287.x · Cited by 27
Beguin, Y. P., & Jaspers, A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.953928 · Cited by 27
IRON DEFICIENCY AND ANEMIA IN PATIENTS WITH CHRONIC HEART FAILURE
Стуклов, Н. И. (2017) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2017-13-5-651-660 · Cited by 38
Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial
Santer, P., Mcgahey, A., Frise, M. C., Petousi, N., Talbot, N. P., Baskerville, R., Bafadhel, M., Nickol, A. H., & Robbins, P. A. (2020) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2020-000577 · Cited by 28
“7 In that study, exercise capacity rose progressively over at least 12 weeks, with a mean increase of ≥ 35 m seen 12 weeks and 24 weeks after FCM.”
Current concepts in the evaluation and management of preoperative anemia
Neef, V., Choorapoikayil, S., Piekarski, F., Schlesinger, T., Meybohm, P., & Zacharowski, K. D. (2021) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000979 · Cited by 28
“However, in case of chronic kidney disease or heart failure, a serum ferritin level <300 ng/ml should be used for detection of ID [17].”
MethodAmbrosy, A. P., von Haehling, S., Kalra, P. R., Court, E., Bhandari, S., McDonagh, T. A., & Cleland, J. G. F. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.04.042 · Cited by 33
Doehner, W., Scherbakov, N., Schellenberg, T., Jankowska, E. A., Scheitz, J. F., von Haehling, S., & Joebges, M. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12927 · Cited by 31
Caravita, S., Faini, A., Vignati, C., Pelucchi, S., Salvioni, E., Cattadori, G., Baratto, C., Torlasco, C., Contini, M. C., Villani, A., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2628 · Cited by 26
Management of Heart Failure With Reduced Ejection Fraction
Rashid, A. M., Khan, M. S., Fudim, M., DeWald, T. A., DeVore, A. D., & Butler, J. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101596 · Cited by 35
Iron deficiency in pulmonary vascular disease: pathophysiological and clinical implications
Martens, P., Yu, S., Larive, B., Borlaug, B. A., ERZURUM, S. C., Farha, S., Finet, J. E., Grünig, G., Hemnes, A. R., Hill, N. S., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad149 · Cited by 26
Vukadinović, D., Abdin, A., Emrich, I. E., Schulze, P. C., von Haehling, S., & Böhm, M. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02207-2 · Cited by 29
Prognostic Value of Three Iron Deficiency Definitions in Patients with Advanced Heart Failure
Papadopoulou, C., Reinhold, J., Grüner‐Hegge, N., Kydd, A. C., Bhagra, S. K., Parameshwar, K. J., Lewis, C. J., Martinez, L., & Pettit, S. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2949 · Cited by 28
Borovka, M., Teruya, S. L., Alvarez, J., Helmke, S. T., & Maurer, M. S. (2013) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2013.08.508 · Cited by 25
Prescher, S., Schoebel, C., Koehler, K., Deckwart, O., Wellge, B., Honold, M., Hartmann, O., Winkler, S., & Koehler, F. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316671438 · Cited by 27
Mitochondrial Therapies in Heart Failure
von Hardenberg, A., & Maack, C. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_123 · Cited by 27
ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia?
Vecchio, L. D., & Minutolo, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040839 · Cited by 37
Intravenous Iron in Heart Failure: Beyond Targeting Anemia
Silverberg, D. S., Iaina, A., Schwartz, D., & Wexler, D. (2010) · Current Heart Failure Reports · doi:10.1007/s11897-010-0034-4 · Cited by 26
Iron therapy for pre-operative anaemia
Ng, O., Keeler, B. D., Mishra, A., Simpson, A., Neal, K. R., Brookes, M., & Acheson, A. G. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011588 · Cited by 26
Iron deficiency in myocardial ischaemia: molecular mechanisms and therapeutic perspectives
Corradi, F., Masini, G., Bucciarelli, T., & Caterina, R. D. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad146 · Cited by 28
Ahmed, M., Shafiq, A., Javaid, H., Singh, P., Shahbaz, H., Maniya, M. T., Jain, H., Shakir, N., Cheema, H. A., Ahmad, A. N., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14905 · Cited by 33
“Contrary to the FAIR-HF study, 9 which was potentially overly brief in duration, the CONFIRM-HF trial 10 discovered a statistically signi fi cant reduction in overall HF hospitalizations with IV iron.”
Treating iron deficiency in patients with heart failure: what, why, when, how, where and who
Graham, F. J., Guha, K., Cleland, J. G. F., & Kalra, P. R. (2024) · Heart · doi:10.1136/heartjnl-2022-322030 · Cited by 29
The clinical significance of anaemia and disturbed iron homeostasis in chronic respiratory failure
Schneckenpointner, R., Jörres, R. A., Meidenbauer, N., Kollert, F., Pfeifer, M. A., & Budweiser, S. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12216 · Cited by 26
Lim, E.-A., Sohn, H.-S., Lee, H., & Choi, S.-E. (2014) · Cost Effectiveness and Resource Allocation · doi:10.1186/1478-7547-12-19 · Cited by 32
de Isla, L. P., Bayés‐Genís, A., Sanchís, J. M., & Heras, M. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70037-3 · Cited by 25
Ambrosy, A. P., Fitzpatrick, J. K., Tabada, G. H., Gurwitz, J. H., Artz, A. S., Schrier, S. L., Rao, S. V., Reynolds, K., Smith, D. H., Peterson, P. N., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.03.020 · Cited by 26
Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
Akizawa, T., Tanaka‐Amino, K., Otsuka, T., & Yamaguchi, Y. (2021) · American Journal of Nephrology · doi:10.1159/000519043 · Cited by 28
Sindone, A. P., Haikerwal, D., Audehm, R. G., Neville, A. M., Lim, K., Parsons, R. W., Piazza, P., & Liew, D. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13661 · Cited by 25
Zhu, S., Liu, C., Zhao, C., Chen, G., Meng, S., Ma, H., Xiang, M., & Xie, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.874846 · Cited by 29
“Subsequent intravenous iron repletion improved the prognosis of HF patients with ID (Anker et al., 2009; Ponikowski et al., 2015; van Veldhuisen et al., 2017).”
BackgroundDugan, C., Cabolis, K., Miles, L. F., & Richards, T. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13114 · Cited by 30
“Twelve studies used a single-dose administration,(18,23,33,34,38,40,41,43,45,48,50,52) whereas nine used repeat dosing at various points throughout the study.(19,35,39,42,44,46,47,49,51) Ferric carboxymaltose was used in thirteen studies, iron isomaltoside (ferric derisomaltose) was used in five studies,(40,41,43,45,4…”
MethodIron metabolism and regulation by neutrophil gelatinase-associated lipocalin in cardiomyopathy
Chan, Y. K., Sung, H. K., & Sweeney, G. (2015) · Clinical Science · doi:10.1042/cs20150075 · Cited by 27
A randomized trial of budiodarone in paroxysmal atrial fibrillation
For the PASCAL Investigators, Ezekowitz, M. D., Nagarakanti, R., Lubiński, A., Bandman, O., Canafax, D. M., Ellis, D., Milner, P. G., Ziola, M., Thibault, B., et al. (2011) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-011-9636-3 · Cited by 28
Inefficacy Interim Monitoring Procedures in Randomized Clinical Trials: The Need to Report
Korn, E. L., & Freidlin, B. (2011) · The American Journal of Bioethics · doi:10.1080/15265161.2010.546471 · Cited by 28
Iron deficiency anemia in heart failure
Arora, N. P., & Ghali, J. K. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9342-y · Cited by 31
Matsumura, T., Saito, T., Fujimura, H., & Sakoda, S. (2012) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.52.211 · Cited by 25
Oxidative effect of several intravenous iron complexes in the rat
Bailie, G. R., Schuler, C., Leggett, R. E., Li, H., Li, H.-D., Patadia, H., & Levin, R. M. (2013) · BioMetals · doi:10.1007/s10534-013-9632-4 · Cited by 26
Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin
Ruifrok, W.-P. T., Qian, C., Silljé, H. H. W., van Goor, H., van Veldhuisen, D. J., van Gilst, W. H., & de Boer, R. A. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0710-6 · Cited by 31
Colet, J. C., Rubio-Rodríguez, D., Rubio‐Terres, C., Enjuanes, C., Gutzwiller, F. S., Anker, S. D., & Ponikowski, P. P. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.10.010 · Cited by 25
Self-citationPrevalence and spectrum of iron deficiency in heart failure patients in south Rajasthan
Sharma, S. K., Agarwal, S. K., Bhargava, K., Sharma, M. K., Chopra, K., & Arumugam, G. (2016) · Indian Heart Journal · doi:10.1016/j.ihj.2015.10.387 · Cited by 25
Zeller, T., Altay, A., Waldeyer, C., Appelbaum, S., Ojeda, F., Ruhe, J., Schnabel, R. B., Lackner, K. J., Blankenberg, S., & Karakas, M. (2018) · Biomolecules · doi:10.3390/biom8030043 · Cited by 25
González‐Costello, J., Colet, J. C., Lupón, J., Enjuanes, C., de Antonio, M., Fuentes, L., Moliner, P., Farré, N., Zamora, E., Manito, N., et al. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0942-x · Cited by 25
Saudi Heart Association (SHA) guidelines for the management of heart failure
AlHabeeb, W., Alayoubi, F., Alghalayini, K. W., Ghofaili, F. A., Hebaishi, Y. A., Al‐Jazairi, A. S., Al-Mallah, M. H., Almasood, A. S., Qaseer, M. A., AlSaif, S. M., et al. (2019) · Journal of the Saudi Heart Association · doi:10.1016/j.jsha.2019.06.004 · Cited by 30
“The FAIR-HF trial, involving 459 patients, showed that administering intravenous iron to patients with CHF and iron deficiency with or without anemia, improved symptoms, functional capacity, and QoL [137].”
MethodInfluentialJacob, C., Altevers, J., Barck, I., Hardt, T., Braun, S. B., & Greiner, W. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12485 · Cited by 29
Pezel, T., Audureau, É., Mansourati, J., Baudry, G., Driss, A. B., Durup, F., Fertin, M. J., Godreuil, C., Jeanneteau, J., Kloëckner, M., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13245 · Cited by 34
“Indeed, as previously mentioned, intravenous IS, in France, requires a short-stay hospitalization to manage possible hypersensitivity.(9) Consequently, intravenous IS is”
BackgroundPacker, M., Anker, S. D., Butler, J., Cleland, J. G. F., Kalra, P. R., Mentz, R. J., Ponikowski, P. P., & Talha, K. M. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3237 · Cited by 32
Self-citationBabitt, J. L., Berns, J. S., Bozkurt, B., Khedairy, R. S. C., Cuevas, Y., Effa, E. E., Eisenga, M. F., Fishbane, S., Ginzburg, Y. Z., Haase, V. H., et al. (2026) · Kidney International · doi:10.1016/j.kint.2025.06.005 · Cited by 47
Contemporary Medical Management of Systolic Heart Failure
Nair, A. P., Timoh, T., & Fuster, V. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-1424 · Cited by 25
Erythropoietin response to anaemia in heart failure
Montero, D., Haider, T., & Flammer, A. J. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318790823 · Cited by 27
Santas, E., Miñana, G., Cardells, I., Palau, P., Llàcer, P., Fácila, L., Almenar, L., López-Lereu, M. P., Monmeneu, J. V., Sanchís, J. M., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13053 · Cited by 24
Butler, J., Khan, M. S., Friede, T., Jankowska, E. A., Fabien, V., Goehring, U.-M., Dorigotti, F., Metra, M., Piña, I. L., Coats, A. J. S., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2478 · Cited by 30
Self-citationPATHOPHYSIOLOGICAL MECHANISMS CONTRIBUTING TO RENAL DYSFUNCTION IN CHRONIC HEART FAILURE
Damman, K., Kalra, P. R., & Hillege, H. L. (2010) · Journal of Renal Care · doi:10.1111/j.1755-6686.2010.00172.x · Cited by 30
Reed, B. N., Blair, E. A., Thudium, E. M., Waters, S. B., Sueta, C. A., Jensen, B. C., & Rodgers, J. E. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1525 · Cited by 24
Palazzuoli, A., Quatrini, I., Calabrò, A., Antonelli, G., Caputo, M., Campagna, M. S., Franci, B., & Nuti, R. (2010) · Clinical and Experimental Medicine · doi:10.1007/s10238-010-0100-y · Cited by 26
When the Heart Runs Out of Heartbeats: Treatment Options for Refractory End-Stage Heart Failure
Ahmad, T., Patel, C. B., Milano, C. A., & Rogers, J. G. (2012) · Circulation · doi:10.1161/circulationaha.112.097337 · Cited by 25
Heart failure with multiple comorbidities
Moe, G. W. P. L. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000257 · Cited by 29
Dzięgała, M., Kasztura, M., Kobak, K. A., Bania, J., Banasiak, W., Ponikowski, P. P., & Jankowska, E. A. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5705 · Cited by 25
Self-citationTorto, A. D., Corrieri, N., Vignati, C., Gentile, P., Cattadori, G., Paolillo, S., & Agostoni, P. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.07.071 · Cited by 24
Paterek, A., Kępska, M., Sochanowicz, B., Chajduk, E., Kołodziejczyk-Czepas, J., Polkowska–Motrenko, H., Kruszewski, M. K., Leszek, P., Mackiewicz, U., & Ma̧czewski, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-33277-2 · Cited by 25
Optimizing Perioperative Blood and Coagulation Management During Cardiac Surgery
Meesters, M. I., & von Heymann, C. (2019) · Anesthesiology Clinics · doi:10.1016/j.anclin.2019.08.006 · Cited by 28
Alayón, C. G., Crespo, C. P., Pedrosa, S. M., Benítez, J. M., Flores, E. I., Rodríguez, I. S., Medina, R., & García-Sánchez, V. (2018) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2017.07.014 · Cited by 24
Health-related quality of life and anemia in hospitalized patients with heart failure
Kraai, I. H., Luttik, M. L., Johansson, P., de Jong, R. M., van Veldhuisen, D. J., Hillege, H. L., & Jaarsma, T. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.05.036 · Cited by 28
Anemia and Iron Deficiency — New Therapeutic Targets in Heart Failure?
Dec, G. W. (2009) · New England Journal of Medicine · doi:10.1056/nejme0910313 · Cited by 28
Hiraiwa, H., Yura, Y., Okumura, T., & Murohara, T. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10418-6 · Cited by 27
“The FAIR-HF trial showed that treat-ment with intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency with or without anemia improved symptoms and quality of life [84].”
BackgroundBiase, N. D., Punta, L. D., L’Hoyes, W., Pellicori, P., Cleland, J. G. F., Masini, G., Gargani, L., Ferreira, S. M., Hoedemakers, S., Fiore, V. D., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3534 · Cited by 27
Anemia management in chronic kidney disease: Intravenous iron steps forward
Coyne, D. W., & Auerbach, M. (2010) · American Journal of Hematology · doi:10.1002/ajh.21682 · Cited by 23
McCullough, P. A., Uhlig, K., Neylan, J. F., Pérgola, P. E., & Fishbane, S. N. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.04.062 · Cited by 26
Miles, L. F., Larsen, T., Bailey, M., Burbury, K. L., Story, D., & Bellomo, R. (2019) · Anaesthesia · doi:10.1111/anae.14870 · Cited by 23
Jhund, P. S., Petrie, M. C., Robertson, M., Mark, P. B., MacDonald, M. R., Connolly, E. C., Anker, S. D., Bhandari, S., Farrington, K., Kalra, P. A., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.04.005 · Cited by 29
Self-citationSong, J. W., Soh, S., Shim, J., Lee, S. H., Lee, S. H., Kim, H.-B., Kim, M.-Y., & Kwak, Y. L. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000005011 · Cited by 25
Zannad, F. M., Alikhaani, J. D., Alikhaani, S., Butler, J., Gordon, J. P., Jensen, K., Khatib, R., Mantovani, L. G., Martinez, R., Moore, W., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2828 · Cited by 27
Feuerstein, A., Schoenrath, F., Belyavskiy, E., Knierim, J., Friede, T., Placzek, M., Bach, D., Pieske‐Kraigher, E., Herrmann‐Lingen, C., Westenfeld, R., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3032 · Cited by 29
Suzuki, T., Hanawa, H., Jiao, S., Ohno, Y., Hayashi, Y., Yoshida, K., Kashimura, T., Obata, H., & Minamino, T. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.01.008 · Cited by 23
Colet, J. C., Rubio-Rodríguez, D., Rubio‐Terres, C., Enjuanes, C., Gutzwiller, F. S., Anker, S. D., & Ponikowski, P. P. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.10.011 · Cited by 23
Self-citationStallmach, A., & Büning, C. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1096929 · Cited by 23
Targets for Heart Failure With Preserved Ejection Fraction
Nanayakkara, S., & Kaye, D. M. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.723 · Cited by 23
Stack, A. G., Alghali, A., Li, X., Ferguson, J. P., Casserly, L. F., Cronin, C. J., Reddan, D. N., Hussein, W. F., & Elsayed, M. (2017) · Clinical Kidney Journal · doi:10.1093/ckj/sfx060 · Cited by 29
Management of Anaemia of Chronic Disease: Beyond Iron-Only Supplementation
Pasini, E., Corsetti, G., Romano, C., Aquilani, R., Scarabelli, T. M., Chen-Scarabelli, C. A., & Dioguardi, F. S. (2021) · Nutrients · doi:10.3390/nu13010237 · Cited by 23
“Intravenous ferric carboxymaltose previously demonstrated improved symptoms, functional capacity and quality of life in HF patients, even in the absence of anaemia, in the FAIR-HF clinical trial [10].”
BackgroundNoumi, B., Teruya, S. L., Salomon, S., Helmke, S. T., & Maurer, M. S. (2011) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2010.00208.x · Cited by 25
Iron Metabolism, Iron Deficiency and Disorders of Haem Synthesis
Hoffbrand, A. V., Hershko, C., & Camaschella, C. (2010) · Wiley eBooks · doi:10.1002/9781444323160.ch3 · Cited by 25
Intravenous iron therapy in pediatrics: who should get it and when is the right time?
Cohen, C. T., & Powers, J. M. (2023) · Hematology · doi:10.1182/hematology.2023000496 · Cited by 22
Beigel, F., Löhr, B., Laubender, R. P., Tillack, C., Schnitzler, F., Breiteneicher, S., Weidinger, M., Göke, B., Seiderer, J., Ochsenkühn, T., et al. (2011) · Digestion · doi:10.1159/000333091 · Cited by 22
Prevalence and Severity of Anemia in Children Hospitalized with Acute Heart Failure
Goldberg, J. F., Shah, M. D., Kantor, P. F., Rossano, J. W., Shaddy, R. E., Chiou, K., Hanna, J. M., Hagan, J. L., Cabrera, A. G., Jeewa, A., et al. (2016) · Congenital Heart Disease · doi:10.1111/chd.12355 · Cited by 23
Okonko, D. O., Jouhra, F., Abu‐Own, H., Filippatos, G. S., Colet, J. C., Chainey, S., Mori, C., Ponikowski, P. P., & Anker, S. D. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12462 · Cited by 23
“Baseline characteristics of the FAIR-HF cohort have been previously published.(12) In brief, the clinical and laboratory features of patients at enrolment were similar between those”
MethodInfluentialSelf-citationSwiss Delphi study on iron deficiency
Nowak, A., Angelillo‐Scherrer, A., Betticher, D. C., Dickenmann, M., Guessous, I., Juillerat, P., de Korte, W. J. A., Neuner‐Jehle, S., Pfister, O., Surbek, D., et al. (2019) · Swiss Medical Weekly · doi:10.4414/smw.2019.20097 · Cited by 24
Metadata
- Authors
- Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., Kirwan, B.-A., Mori, C., von Eisenhart Rothe, B., Pocock, S. J., Poole-Wilson, P. A., & Ponikowski, P.
- Affiliations
- Stavanger University Hospital (NO)
- Lund University (SE)
- University of Bergen (NO)
- Medizinische Hochschule Hannover (DE)
- University Hospital Zurich (CH)
- Pirogov Russian National Research Medical University (RU)
- State Oil Company of Azerbaijan Republic (Azerbaijan) (AZ)
- Vifor Pharma (Switzerland) (CH)
- London School of Hygiene & Tropical Medicine (GB)
- Imperial College London (GB)
- Wroclaw Medical University (PL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-17
- Volume
- 361
- Issue
- 25
- Pages
- 2436-2448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2148669301
- Cited by
- 2,083
- References
- 26
- Citations by year
- 2026: 101 · 2025: 131 · 2024: 145 · 2023: 156 · 2022: 162 · 2021: 190 · 2020: 128 · 2019: 129 · 2018: 113 · 2017: 133 · 2016: 101 · 2015: 115 · 2014: 102 · 2013: 93 · 2012: 106
- FWCI
- 62.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- University of Bedfordshire Repository (University of Bedfordshire) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Teva Pharmaceutical Industries
- Vifor Pharma
- Servier
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- ferric carboxymaltose, intravenous iron, chronic heart failure, iron deficiency, anemia, reduced left ventricular ejection fraction, NYHA functional class, symptom improvement, functional capacity, 6-minute walk test, health-related quality of life, ferritin, transferrin saturation, adverse events, mortality, serious adverse events, iron deficiency anemia
- MeSH terms
- Iron Deficiencies, Aged, Chronic Disease, Female, Ferric Compounds, Ferritins, Follow-Up Studies, Heart Failure, Hematinics, Humans, Male, Maltose, Quality of Life, Stroke Volume, Ventricular Dysfunction, Left, Anemia, Iron-Deficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.